HOME >> MEDICINE >> NEWS
New analysis shows early intervention with Actonel reduces first vertebral fracture risk

Cincinnati, Ohio; Bridgewater, N.J. (June 20, 2002) Postmenopausal women with low spinal bone mineral density (BMD) and no previous history of vertebral fracture, who received Actonel (risedronate sodium tablets) 5 mg daily for up to three years, were 75 percent less likely to experience a first vertebral fracture than women in the control group, according to a new analysis. Published in the June issue of the journal Osteoporosis International, the results confirm the fracture reduction efficacy of Actonel in patients without vertebral fractures.

Vertebral fractures are among the most common osteoporotic fractures. In the U.S., an estimated 700,000 vertebral fractures occur every year. Data show that among postmenopausal women who sustain a vertebral fracture, one out of five will suffer their next vertebral fracture within just one year, potentially leading to a fracture cascade.

"Osteoporosis, long considered a slow developing disease, can actually progress quickly once a fracture occurs. The ability to prevent a first fracture is crucial for clinicians in the fight against osteoporosis. This is extremely important since osteoporosis affects more than 10 million people in the U.S.," said Robert Heaney, MD, of Creighton University in Omaha, Nebraska. "This 75 percent reduction in the risk of first fracture helps confirm that Actonel is a clinically significant treatment for postmenopausal women with osteoporosis."

The analysis assessed the risk of the first vertebral fracture in 640 postmenopausal women enrolled in four previously reported studies. The women had low lumbar spine BMD (T score <-2.5) and no vertebral fractures at baseline. The Actonel 5 mg daily, placebo-controlled studies ranged in duration from 1.5 to 3 years.

First vertebral fractures were observed in only 2.6 percent of the women who received Actonel 5 mg daily compared to 9.4 percent in the control group (which translates to a 75 percent risk fracture r
'"/>


20-Jun-2002


Page: 1 2

Related medicine news :

1. New system for the analysis of facial movement in three dimensions
2. Re-analysis of large trials shows greatest benefit of chemotherapy in ER-negative tumors
3. Fatally flawed legal analysis will not stand
4. Subanalysis finds patient-controlled, transdermal pain management system may be comparable
5. New analysis links breastfeeding to reduced risk of childhood leukemia
6. Calling for standards in cardiology data collection and analysis
7. OHSU receives grant to study evolutionary computing for biomedical image analysis
8. HPV testing helps identify potential cases of cervical cancer, meta-analysis suggests
9. A common cleanser is cheaper and faster way to separate DNA for genetic analysis
10. Large-scale analysis of women with androgen excess: thorough treatment can reduce symptoms
11. New Commonwealth Fund analysis compares candidtes health care reform proposals

Post Your Comments:
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... the body,s system for repairing damage to the genetic ... as it may seem, those compounds are sparking optimism ... by a mutation in BRCA, a gene that made ... mutation. The compounds, termed PARP inhibitors, are the topic ... Chemical & Engineering News . C&EN is the ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...
(Date:6/19/2013)... 2013 Many trying-to-conceive couples seek ... necessary, according to a recent study ... The results of this research confirm what Fairhaven ... decade – that trying-to-conceive women would benefit from ... body weight. Fairhaven Health is a leading provider ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... 2013   Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain.  This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: